What to Discuss After a Missed or Delayed Dose of Staying on Low-Dose Wegovy
The Wegovy injection label sets a two-day rule. If the next scheduled injection is more than two days away, the missed one is given as soon as possible. If it is less than two days away, that dose is skipped and treatment resumes on the usual day. Two or more consecutive missed injections change the answer entirely.
The rules as the labeling states them
These provisions are short, and the second one is the one people have not read.
| Situation | What the labeling directs |
|---|---|
| One injection missed, next scheduled dose more than 2 days away | Give the missed dose as soon as possible |
| One injection missed, next scheduled dose less than 2 days away | Skip it and resume on the regular weekly day |
| Two or more consecutive injections missed | Reinitiate escalation at a lower amount to reduce gastrointestinal risk |
| One tablet missed | Skip it and take the next dose the following day |
Nothing in that text permits doubling up, and nothing invites a patient to decide independently where reescalation should restart after a longer gap. The second question belongs to the prescriber.
The two-day rule is short enough that people often check it against more than one source before calling anyone. Ro, Hims and Hers, and Henry Meds restate the missed-injection and reescalation wording in plainer language, manufacturer routes like NovoCare and LillyDirect do the same, and a provider page such as HealthRX’s Wegovy summary carries the same instructions the label uses. Cross-checking a couple of them is a reasonable first move, though the restart question after a long gap still lands with the prescriber.
Why two missed weeks is a different category
Tolerance to gastrointestinal effects is built rather than permanent. It develops over weeks of steady exposure, which is why titration works and why the labeling frames the ramp as a way of reducing the risk of those reactions. After a long enough pause, the adaptation that made a given amount comfortable is no longer reliably there.
Resuming at the previous amount after such a gap is the mechanism behind a lot of miserable restart weeks that get attributed to a bad batch or an unlucky reaction. The labeling anticipates exactly that, which is why the instruction is to step back and climb again rather than to pick up where treatment stopped.
This applies whether or not the person had been sitting at an intermediate amount by design. The rule is about consecutive missed doses, not about how far up the schedule they had gone.
The reason for the gap is clinical information
Prescribers cannot act on a gap they only hear about as “I missed a couple.” The underlying cause changes what should happen next, and each of these produces a different plan.
A supply interruption at the pharmacy suggests a conversation about presentations and lead times. A coverage denial or a price increase raises whether the current maintenance amount is sustainable at all, and whether appeal routes or alternative channels are worth pursuing. Symptoms that made someone skip deliberately are an adverse event report, not a scheduling problem. Travel and storage difficulties point at logistics. Simple forgetting points at reminders and at whether the injection day still suits the person’s week.
Naming the actual reason converts a lost fortnight into a decision the clinician can make. Reporting only the number of missed doses leaves them guessing.
When a gap quietly becomes a new dose
The pattern worth watching for is drift. Someone under financial pressure spaces injections out, then spaces them further, and ends up on an unplanned schedule nobody prescribed and nobody is monitoring. It rarely looks like a decision from the inside. It looks like managing.
The clinical problem is not that a lower maintenance amount is illegitimate. For weight reduction in adults the labeling names 1.7 mg alongside the recommended 2.4 mg as a maintenance option, chosen by the prescriber with response and tolerability in view. The problem is that a self-arranged schedule is invisible to the person responsible for interpreting the results, so a plateau cannot be read correctly and a symptom cannot be placed in context.
Cost pressure is a real reason this happens, and it is worth raising directly rather than solving privately. Coverage for weight-management medication differs sharply between commercial plans and Medicare Part D, and many people pay cash. The terms of the service matter as much as the sticker price here: whether follow-up is included, how fast a prescriber replies, and what a change of plan costs. Endocrinology practices, manufacturer channels such as NovoCare Pharmacy and LillyDirect, and telehealth options ranging from Ro and Hims & Hers to LifeMD or a supervised compounded GLP-1 provider set those terms differently, and the differences show up precisely when something has gone wrong.
Switching forms is a defined procedure, not a workaround
People sometimes treat a gap as a chance to change form, usually because one is cheaper or easier to obtain that week. The labeling handles switching as a specific procedure rather than an improvisation. Adults on 2.4 mg injection may move to 25 mg tablets, starting one week after the last injection. Those on 25 mg tablets may move to 2.4 mg injection the day after the last tablet, and where tablets were not tolerated, a switch to 1.7 mg injection is suggested instead.
Those instructions describe planned transitions in stable patients. They do not describe what to do after an unplanned interruption, which is a separate question with a separate answer.
Compounded prescriptions need their own instructions
Compounded semaglutide is not FDA-approved and is not reviewed before marketing for safety, effectiveness, or manufacturing quality. Concentration varies by pharmacy, so the branded missed-dose rules cannot be assumed to transfer to a compounded vial, and neither can any restart schedule.
The instructions that apply are the ones issued with that prescription. A gap is a reason to contact the prescribing service rather than to reconstruct a plan from a Wegovy label describing a different product.
What to bring to the conversation
Four things make the discussion productive: how many consecutive doses were missed and on which dates, the reason, any symptoms during or after the gap, and what the current supply situation is. The prescriber also needs to know about anything else that changed, including new medications, a planned procedure, or pregnancy plans, since semaglutide has a long half-life and the labeling asks that treatment stop at least two months before a planned pregnancy for weight or cardiovascular indications.
One screening point holds regardless: semaglutide carries a boxed warning for thyroid C-cell tumors seen in rodents and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.
Frequently asked questions
Can two doses be taken together to catch up?
No. The labeling describes taking a missed injection when the next one is more than two days away, or skipping it when it is closer, and it never describes combining doses. Concurrent use with another semaglutide product or another GLP-1 receptor agonist is separately not recommended.
How far back does escalation restart after a long gap?
The labeling directs reinitiating at a lower amount without fixing a single step, so the answer depends on how long the pause lasted, what was tolerated previously, and the person’s current condition. That makes it a prescriber decision rather than something to work out from the schedule alone.
Does the tablet form use the same rule?
No. Because tablets are taken daily rather than weekly, a missed tablet is simply skipped and the next dose is taken the following day. Doubling up is not part of the instruction, and the daily schedule means a single miss has a smaller effect than a missed weekly injection.
Is a deliberately delayed dose the same as a missed one?
Clinically it is treated the same way, but the reason matters more. A delay chosen because of symptoms, cost, or supply is information the prescriber needs in order to adjust the plan, and reporting it as a decision rather than an accident tends to produce a more useful response.
